mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia
- PMID: 28807816
- PMCID: PMC5748251
- DOI: 10.1016/j.freeradbiomed.2017.08.009
mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia
Abstract
The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase involved in the regulation of protein synthesis and degradation, longevity and cytoskeletal formation. The mTOR pathway represents a key growth and survival pathway involved in several diseases such as cancer, obesity, cardiovascular disease and neurodegenerative diseases. Numerous studies linked the alterations of mTOR pathway to age-dependent cognitive decline, pathogenesis of Alzheimer disease (AD) and AD-like dementia in Down syndrome (DS). DS is the most frequent chromosomal abnormality that causes intellectual disability. The neuropathology of AD in DS is complex and involves impaired mitochondrial function, defects in neurogenesis, increased oxidative stress, altered proteostasis and autophagy networks as a result of triplication of chromosome 21(chr 21). The chr21 gene products are considered a principal neuropathogenic moiety in DS. Several genes involved respectively in the formation of senile plaques and neurofibrillary tangles (NFT), two main pathological hallmarks of AD, are mapped on chr21. Further, in subjects with DS the activation of mTOR signaling contributes to Aβ generation and the formation of NFT. This review discusses recent research highlighting the complex role of mTOR associated with the presence of two hallmarks of AD pathology, senile plaques (composed mostly of fibrillar Aß peptides), and NFT (composed mostly of hyperphosphorylated tau protein). Oxidative stress, associated with chr21-related Aβ and mitochondrial alterations, may significantly contribute to this linkage of mTOR to AD-like neuropathology in DS.
Keywords: Amyloid β-peptide; Down syndrome; Neurofibrillary tangles; Oxidative stress; Senile plaques; mTOR.
Copyright © 2017 Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain.Biochim Biophys Acta. 2014 Jul;1842(7):1144-53. doi: 10.1016/j.bbadis.2014.04.007. Epub 2014 Apr 13. Biochim Biophys Acta. 2014. PMID: 24735980 Free PMC article.
-
Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.J Neurochem. 2015 Jun;133(5):739-49. doi: 10.1111/jnc.13037. Epub 2015 Feb 26. J Neurochem. 2015. PMID: 25645581
-
HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.Free Radic Biol Med. 2017 Oct;111:262-269. doi: 10.1016/j.freeradbiomed.2016.10.508. Epub 2016 Nov 10. Free Radic Biol Med. 2017. PMID: 27838436 Free PMC article. Review.
-
Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease.Mol Neurobiol. 2024 Dec;61(12):10941-10955. doi: 10.1007/s12035-024-04257-7. Epub 2024 May 30. Mol Neurobiol. 2024. PMID: 38816674 Review.
-
Brain insulin resistance in Down syndrome: Involvement of PI3K-Akt/mTOR axis in early-onset of Alzheimer's disease and its potential as a therapeutic target.Biochem Biophys Res Commun. 2024 Nov 12;733:150713. doi: 10.1016/j.bbrc.2024.150713. Epub 2024 Sep 17. Biochem Biophys Res Commun. 2024. PMID: 39307112 Review.
Cited by
-
Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer's Disease and Diabetes.Biomedicines. 2021 May 19;9(5):576. doi: 10.3390/biomedicines9050576. Biomedicines. 2021. PMID: 34069618 Free PMC article. Review.
-
Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials.Antioxidants (Basel). 2020 Aug 3;9(8):692. doi: 10.3390/antiox9080692. Antioxidants (Basel). 2020. PMID: 32756318 Free PMC article. Review.
-
Functional and structural analyses of novel Smith-Kingsmore Syndrome-Associated MTOR variants reveal potential new mechanisms and predictors of pathogenicity.PLoS Genet. 2021 Jul 1;17(7):e1009651. doi: 10.1371/journal.pgen.1009651. eCollection 2021 Jul. PLoS Genet. 2021. PMID: 34197453 Free PMC article.
-
The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome.Neurotherapeutics. 2021 Jan;18(1):340-363. doi: 10.1007/s13311-020-00978-4. Epub 2020 Nov 30. Neurotherapeutics. 2021. PMID: 33258073 Free PMC article.
-
Human Trisomic iPSCs from Down Syndrome Fibroblasts Manifest Mitochondrial Alterations Early during Neuronal Differentiation.Biology (Basel). 2021 Jun 30;10(7):609. doi: 10.3390/biology10070609. Biology (Basel). 2021. PMID: 34209429 Free PMC article.
References
-
- O' Neill C. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease. Exp Gerontol. 2013;48:647–653. - PubMed
-
- Gharibi B, Farzadi S, Ghuman M, Hughes FJ. Inhibition of Akt/mTOR attenuates age-related changes in mesenchymal stem cells. Stem Cells. 2014;32:2256–2266. - PubMed
-
- Martinez-Martinez E, Jurado-Lopez R, Cervantes-Escalera P, Cachofeiro V, Miana M. Leptin, a mediator of cardiac damage associated with obesity. Horm Mol Biol Clin Investig. 2014;18:3–14. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous